EULAR关于难治性及治疗抵抗性银屑病关节炎的考虑要点和共识定义
欧洲抗风湿病联盟(EULAR)多学科工作组制定了4条总体原则、6条考虑要点及2个共识定义,用于识别难治性(D2M)银屑病关节炎人群及其中的治疗抵抗性(TR)亚组。这些定义需在研究中进行检验。
要点
- D2M PsA为涵盖炎症、合并症、心理社会等因素的伞形术语,TR PsA为其亚组。
- TR PsA定义为持续疾病活动并伴活动性炎症的客观证据。
- 考虑要点包括≥2种不同作用机制生物/靶向合成DMARDs治疗失败等标准。
核心结论
- EULAR提出2个共识定义以识别D2M PsA人群,其中包括TR亚组。
- 这些定义需在研究中进行检验,以理解疾病发病机制并改善银屑病关节炎患者的照护。
研究设计与样本
- EULAR多学科国际工作组由27名成员组成,包括风湿科医生、皮肤科医生、健康从业者和患者伙伴。
- 遵循EULAR标准化操作流程,包括系统文献综述和共识过程。
主要发现
- 工作组制定了4条总体原则,涉及尽管接受最佳标准治疗仍有不满意治疗反应的PsA患者比例,其原因可能是多因素的。
- 6条考虑要点突出与后续定义相关的标准,包括对≥2种不同作用机制生物/靶向合成DMARDs未能达到或维持应答。
- 考虑要点还包括管理风湿科医生和/或患者认为有问题的体征和症状,以及在存在骨骼外表现和/或合并症和/或炎症活动客观证据时持续疾病活动的证据。
- 制定了2个定义:D2M PsA为伞形术语,包括炎症、合并症、心理社会或其他因素等驱动因素。
- TR PsA定义为持续疾病活动并伴活动性炎症的客观证据,纳入D2M PsA定义中。
关键数值与推荐
- D2M PsA定义为涵盖炎症、合并症、心理社会或其他因素等驱动因素的伞形术语。
- TR PsA定义为持续疾病活动并伴活动性炎症的客观证据。
- 考虑要点包括对≥2种不同作用机制生物/靶向合成DMARDs未能达到或维持应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to develop evidence-based points to consider (PtC) and consensus definitions of difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA). METHODS: A multidisciplinary international European Alliance of Associations for Rheumatology (EULAR) task force (TF) of 27 members, including rheumatologists, dermatologists, health practitioners, and patient partners, was established, and the EULAR standardised operating procedures, including a systematic literature review and a consensus process, were followed. RESULTS: The TF formulated 4 overarching principles addressing the proportion of patients with PsA with an unsatisfactory treatment response despite the best standard of care, and for which the causes are likely multifactorial. Six PtC highlight criterion relevant for subsequent definitions including failure to achieve or maintain response to ≥2 biological/targeted synthetic disease-modifying antirheumatic drugs with ≥2 different mechanisms of action; management of signs and symptoms perceived as problematic by the rheumatologist and/or the patient, and evidence of persistent disease activity in the presence of extramusculoskeletal manifestations and/or comorbidities and/or objective evidence of inflammatory activity. Finally, the following 2 definitions were developed: (1) D2M PsA, an umbrella term including drivers such as inflammation, comorbidities, psychosocial or other factors, incorporating (2) TR PsA, defined by persistent disease activity and objective evidence of active inflammation. CONCLUSIONS: EULAR proposes 2 consensus definitions to identify a D2M PsA population, including a TR subgroup. These definitions should now be tested in research studies to understand disease pathogenesis and improve care for people living with PsA.
引用
- Marzo-Ortega H, Harrison SR, Fragoulis GE, et al. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2025. PMID: 41168056. doi:10.1016/j.ard.2025.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。